Literature DB >> 19685543

Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours.

Carlotta Granchi1, Tiziana Funaioli, Janine T Erler, Amato J Giaccia, Marco Macchia, Filippo Minutolo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19685543      PMCID： PMC3050608          DOI： 10.1002/cmdc.200900247

Source DB:  PubMed          Journal:  ChemMedChem        ISSN： 1860-7179            Impact factor:   3.466


× No keyword cloud information.
  27 in total

1.  Lathyrus factor activity of beta-aminopropionitrile and related compounds.

Authors:  T E BACHHUBER; J J LALICH; D M ANGEVINE; E D SCHILLING; F M STRONG
Journal:  Proc Soc Exp Biol Med       Date:  1955-06

Review 2.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

3.  Synthesis by radical cyclization and cytotoxicity of highly potent bioreductive alicyclic ring fused [1,2-a]benzimidazolequinones.

Authors:  Mary Lynch; Sarah Hehir; Paul Kavanagh; Dónal Leech; John O'Shaughnessy; Michael P Carty; Fawaz Aldabbagh
Journal:  Chemistry       Date:  2007       Impact factor: 5.236

4.  Aminoalkylaziridines as substrates and inhibitors of lysyl oxidase: specific inactivation of the enzyme by N-(5-aminopentyl)aziridine.

Authors:  N Nagan; P S Callery; H M Kagan
Journal:  Front Biosci       Date:  1998-05-01

5.  Lysyl oxidase is essential for hypoxia-induced metastasis.

Authors:  Janine T Erler; Kevin L Bennewith; Monica Nicolau; Nadja Dornhöfer; Christina Kong; Quynh-Thu Le; Jen-Tsan Ashley Chi; Stefanie S Jeffrey; Amato J Giaccia
Journal:  Nature       Date:  2006-04-27       Impact factor: 49.962

6.  Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria.

Authors:  G Liu; K Nellaiappan; H M Kagan
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

Review 7.  Lysyl oxidase: an oxidative enzyme and effector of cell function.

Authors:  H A Lucero; H M Kagan
Journal:  Cell Mol Life Sci       Date:  2006-10       Impact factor: 9.261

Review 8.  Lysyl oxidase mediates hypoxic control of metastasis.

Authors:  Janine T Erler; Amato J Giaccia
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

9.  Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice.

Authors:  Barbara Bedogni; Melony S O'Neill; Scott M Welford; Donna M Bouley; Amato J Giaccia; Nicholas C Denko; Marianne Broome Powell
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

Review 10.  Molecular mechanisms of tumor invasion and metastasis: an integrated view.

Authors:  R A Cairns; R Khokha; R P Hill
Journal:  Curr Mol Med       Date:  2003-11       Impact factor: 2.222
View more
  8 in total

1.  Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.

Authors:  Liam J O'Connor; Cindy Cazares-Körner; Jaideep Saha; Charles N G Evans; Michael R L Stratford; Ester M Hammond; Stuart J Conway
Journal:  Nat Protoc       Date:  2016-03-24       Impact factor: 13.491

Review 2.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

Review 3.  Lysyl oxidase: a potential target for cancer therapy.

Authors:  V M Berlin Grace; C Guruvayoorappan
Journal:  Inflammopharmacology       Date:  2010-11-24       Impact factor: 4.473

4.  Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer.

Authors:  Ennio Tasciotti; Toni Ibrahim; Alessandro De Vita; Chiara Liverani; Roberto Molinaro; Jonathan O Martinez; Kelly A Hartman; Chiara Spadazzi; Giacomo Miserocchi; Francesca Taraballi; Michael Evangelopoulos; Federica Pieri; Alberto Bongiovanni; Laura Mercatali
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

5.  Nerve growth factor promotes lysyl oxidase-dependent chondrosarcoma cell metastasis by suppressing miR-149-5p synthesis.

Authors:  Huey-En Tzeng; Syuan-Ling Lin; Louis Anoop Thadevoos; Ming-Yu Lien; Wei-Hung Yang; Chih-Yuan Ko; Chih-Yang Lin; Yu-Wen Huang; Ju-Fang Liu; Yi-Chin Fong; Hsien-Te Chen; Chih-Hsin Tang
Journal:  Cell Death Dis       Date:  2021-11-23       Impact factor: 8.469

6.  CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and Aurora A.

Authors:  Cindy Cazares-Körner; Isabel M Pires; I Diane Swallow; Samuel C Grayer; Liam J O'Connor; Monica M Olcina; Martin Christlieb; Stuart J Conway; Ester M Hammond
Journal:  ACS Chem Biol       Date:  2013-05-10       Impact factor: 5.100

7.  Targeting lysyl oxidase for molecular imaging in breast cancer.

Authors:  Melinda Wuest; Manuela Kuchar; Sai Kiran Sharma; Susan Richter; Ingrit Hamann; Monica Wang; Larissa Vos; John R Mackey; Frank Wuest; Reik Löser
Journal:  Breast Cancer Res       Date:  2015-08-13       Impact factor: 6.466

8.  Evaluation of Fluorine-18-Labeled α1(I)-N-Telopeptide Analogs as Substrate-Based Radiotracers for PET Imaging of Melanoma-Associated Lysyl Oxidase.

Authors:  Manuela Kuchar; Christin Neuber; Birgit Belter; Ralf Bergmann; Jens Lenk; Robert Wodtke; Torsten Kniess; Jörg Steinbach; Jens Pietzsch; Reik Löser
Journal:  Front Chem       Date:  2018-04-26       Impact factor: 5.221
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.